Predictive Biosciences tapped veteran diagnostics industry executive Kim Blickenstaff, president and CEO of insulin pump developer Tandem Diabetes Care Inc., for its board of directors.
The Lexington, Mass-based cancer diagnostics developer said Blickenstaff’s expertise will come in handy as it readies to bring a non-invasive molecular diagnostic for bladder cancer to market via a recent acquisition.
Predictive bought molecular diagnostics firm OncoDiagnostic Laboratory for an undisclosed amount earlier this month, issuing $1.4 million in stock as part of the deal. The company said Blickenstaff’s appointment to its board plays into its plans for Cleveland-based ODL.
Blickenstaff was co-founder, chairman and CEO of Biosite Inc. until it was bought for $1.8 billion by Inverness Medical Innovations Inc. (NYSE:IMA) in 2007. His resumé includes stints at Hybritech Inc., Baxter Healthcare (NYSE:BAX) and tenures on the boards of SenoRx (NSDQ:SENO) and MediVation Inc. (NSDQ:MDVN).
